Syndax Pharmaceuticals Announces Entinostat Data at 102nd Annual American Association for Cancer Research Meeting
WALTHAM, Mass., March 31, 2011 /PRNewswire/ — Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, today announced 11 posters on entinostat, an oral, highly selective, class I histone deacetylase (HDAC) inhibitor, will be presented at the 102nd Annual American Association for Cancer Research meeting April 2 to April 6 in Orlando, FL.
“The breadth of exciting data being presented at AACR provides additional insight into the opportunities for Syndax to build out our entinostat development program,” said Joanna Horobin, president and chief executive officer of Syndax. “The AACR presentations add to the growing body of evidence supporting the potential for entinostat in solid tumors including the promising results with entinostat in combination with TarcevaÃ‚® in advanced non-small-cell lung cancer which were presented at the end of last year. Recently we completed our randomized, placebo-controlled phase 2 clinical trial in metastatic breast cancer which will be presented at a scientific conference later this year and are aggressively moving forward with a pivotal program in this patient population.”
The following posters will be presented Monday, April 4: Time: 8:00 AM to 12:00 PM EDT: Presentation #: 1146 Multiple HDAC inhibitors (HDACi) reduce the expression of the oncogenic miR-17~92 cluster; a Title: pan HDACi class effect Location: Exhibit Hall A4-C, Poster Section 7 Time: 8:00 AM to 12:00 PM EDT: Presentation #: 1792 Selective class I HDAC inhibitor SNDX-275 enhances anti-tumor survivin vaccine therapy by suppressing Title: regulatory T cells in a model of prostate cancer Location: Exhibit Hall A4-C, Poster Section 32 Time: 1:00 to 5:00 PM EDT: Presentation #: 2018 Combination therapy with vidaza and entinostat suppresses tumor growth and reprograms the Title: epigenome in an orthotopic lung cancer model Location: Exhibit Hall A4-C, Poster Section 3 Time: 1:00 to 5:00 PM EDT: Presentation #: 2572 The histone deacetylase inhibitors (HDACIs) vorinostat and entinostat interact synergistically with the Bcr/Abl, FLT3, and aurora kinase inhibitor KW-2449 to induce apoptosis in imatininb mesylate (IM)-sensitive and -resistant CML and Title: ALL cells Location: Exhibit Hall A4-C, Poster Session 27 Time: 1:00 to 5:00 PM EDT: Presentation #: 2614 Inhibition of class I histone deacetylases attenuates anthracycline induced activation of the Title: ATM pathway Location: Exhibit Hall A4-C, Poster Session 29 Time: 1:00 to 5:00 PM EDT: Presentation #: 2618 DNMT1 as a marker of differential sensitivities to epigenetic therapy of a Kras mutant and Kras wild Title: type human non small cell lung cancer cell line Location: Exhibit Hall A4-C, Poster Session 29 Time: 1:00 to 5:00 PM EDT: Presentation #: 2633 Histone deacetylase inhibitors induce CXCR4 mRNA but Title: antagonize CXCR4 migration Location: Exhibit Hall A4-C, Poster Session 29 The following posters will be presented Tuesday, April 5: Time: 8:00 AM to 12:00 PM EDT: Presentation #: 3519 Histone deacetylase inhibitors upregulates thymidine phosphorylase gene and protein expression and Title: synergize with capecitabine in breast cancer cells Location: Exhibit Hall A4-C, Poster Session 26 Time: 1:00 to 5:00 PM EDT: Presentation #: LB-411 A phase II study of combination epigenetic therapy Title: in advanced non-small cell lung cancer Location: Exhibit Hall A4-C, Poster Session 40 The following posters will be presented Wednesday, April 6: Time: 8:00 AM to 12:00 PM EDT: Presentation #: 5335 The histone deacetylase inhibitor MS-275 sensitizes osteosarcoma cells and osteosarcoma lung metastases to FasL-induced cell death by the downregulation Title: c-FLIP Location: Exhibit Hall A4-C, Poster Session 25 Time: 8:00 AM to 12:00 PM EDT: Presentation #: 5048 Targeting regulators of Chk1 to enhance cytotoxic Title: efficacy of HDAC inhibitors Location: Exhibit Hall A4-C, Poster Session 12
Entinostat is an orally bioavailable, highly selective, class I histone deacetylase (HDAC) inhibitor with a long half-life that allows for weekly or every-other-week dosing. Entinostat is being studied in advanced breast cancer in combination with aromatase inhibitors and recently completed a randomized, placebo-controlled phase 2 trial in this patient population. The results will be presented at a scientific conference later this year. Entinostat also is being studied in various cancers including advanced non-small-cell lung cancer and advanced colorectal cancer in combination with azacitidine. At the end of last year, results were presented from a randomized phase 2 study showing a four-month survival advantage when entinostat was added to erlotinib in patients with lung cancers expressing high levels of E-cadherin. Syndax has several studies ongoing under a cooperative research and development agreement with the National Cancer Institute.
Research has shown that HDACs are involved in the expression of various genes, such as the estrogen receptor, that regulate cell growth, differentiation and apoptosis. Such genes are frequently silenced in cancer cells through the over-expression of enzymes including HDACs. HDACs are therefore recognized as promising targets for cancer treatment. Further, studies have demonstrated that HDAC inhibition can significantly enhance anti-cancer activity when used in combination with a broad range of anti-cancer agents. The potential therefore exists to overcome tumor resistance to targeted agents.
Syndax Pharmaceuticals, Inc. is a Waltham, MA-based, oncology-focused pharmaceutical company. Syndax is building a portfolio of new oncology products to extend and improve the lives of patients by developing and commercializing novel cancer therapies in optimized, mechanistically driven combination regimens. Formed in 2005, the company’s intellectual property is based on work from scientific founder Ronald Evans, Ph.D., recipient of the 2004 Albert Lasker Prize for Basic Medical Research, a Member of the National Academy of Sciences, a professor at the Salk Institute for Biological Studies and a Howard Hughes Medical Institute Investigator. Syndax has worldwide rights to develop and commercialize entinostat and is backed by top-tier Venture Capital firms: Domain Associates, MPM Capital, Avalon, Pappas and Forward Ventures. For more information please visit www.syndax.com.
E. Blair Schoeb
Syndax Pharmaceuticals, Inc
SOURCE Syndax Pharmaceuticals, Inc.